NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 184 filers reported holding NEVRO CORP in Q3 2022. The put-call ratio across all filers is 0.60 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $196,006 | -23.1% | 10,198 | +1.7% | 0.00% | 0.0% |
| Q2 2023 | $254,836 | -27.7% | 10,025 | +2.8% | 0.00% | -33.3% |
| Q1 2023 | $352,535 | -6.2% | 9,752 | +2.8% | 0.00% | -25.0% |
| Q4 2022 | $375,646 | -11.4% | 9,486 | +4.2% | 0.00% | 0.0% |
| Q3 2022 | $424,000 | +7.3% | 9,103 | +0.9% | 0.00% | 0.0% |
| Q2 2022 | $395,000 | -39.0% | 9,023 | +0.7% | 0.00% | -20.0% |
| Q1 2022 | $648,000 | -10.4% | 8,963 | +0.5% | 0.01% | -16.7% |
| Q4 2021 | $723,000 | -30.9% | 8,915 | -0.9% | 0.01% | -33.3% |
| Q3 2021 | $1,047,000 | -29.4% | 8,999 | +0.6% | 0.01% | -25.0% |
| Q2 2021 | $1,482,000 | +11.6% | 8,941 | -6.1% | 0.01% | 0.0% |
| Q1 2021 | $1,328,000 | -18.8% | 9,521 | +0.7% | 0.01% | -20.0% |
| Q4 2020 | $1,636,000 | +20.6% | 9,453 | -3.0% | 0.02% | +15.4% |
| Q3 2020 | $1,357,000 | +66.5% | 9,745 | +42.8% | 0.01% | +18.2% |
| Q2 2020 | $815,000 | +12.0% | 6,823 | -6.3% | 0.01% | -15.4% |
| Q1 2020 | $728,000 | – | 7,279 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 622,615 | $38,920,000 | 8.04% |
| Tamarack Advisers, LP | 160,000 | $10,002,000 | 3.97% |
| Birch Run Capital Advisors, LP | 187,425 | $11,716,000 | 3.72% |
| Prosight Management, LP | 128,765 | $8,049,000 | 3.52% |
| Ratan Capital Management LP | 38,653 | $2,416,000 | 3.44% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 579,463 | $36,222,000 | 1.39% |
| Spark Investment Management LLC | 403,400 | $25,216,000 | 1.17% |
| Sivik Global Healthcare LLC | 50,000 | $3,126,000 | 1.15% |
| ArrowMark Colorado Holdings LLC | 1,882,009 | $117,644,000 | 1.11% |
| PFM Health Sciences, LP | 721,229 | $45,084,000 | 1.00% |